170 related articles for article (PubMed ID: 36961524)
21. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
[TBL] [Abstract][Full Text] [Related]
22. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
[TBL] [Abstract][Full Text] [Related]
23. Beyond the border: the use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines: a retrospective analysis.
Jefremow A; Wiesmueller M; Rouse RA; Dietrich P; Kremer AE; Waldner MJ; Neurath MF; Siebler J
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571964
[TBL] [Abstract][Full Text] [Related]
24. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
25. [Erythrocytosis in patients with hepatocarcinoma in alcoholic cirrhosis: ectopic production of erythropoietin?].
Giovanardi P; Sacchetti C; Cameroni P; Grandi M
Recenti Prog Med; 1998 May; 89(5):250-2. PubMed ID: 9676132
[TBL] [Abstract][Full Text] [Related]
26. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy.
Ohya K; Kawaoka T; Namba M; Uchikawa S; Kodama K; Morio K; Nakahara T; Murakami E; Hiramatsu A; Tsuge M; Yamauchi M; Imamura M; Chayama K; Aikata H
Sci Rep; 2019 Aug; 9(1):12101. PubMed ID: 31431642
[TBL] [Abstract][Full Text] [Related]
27. Association Between Renal Adverse Effects and Mortality in Patients With Hepatocellular Carcinoma Treated With Lenvatinib.
Shimamura Y; Abe K; Maeda T; Matsui T; Ishiguro A; Takizawa H
In Vivo; 2021; 35(3):1647-1653. PubMed ID: 33910848
[TBL] [Abstract][Full Text] [Related]
28. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
[TBL] [Abstract][Full Text] [Related]
29. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
Ikesue H; Yamamoto H; Hirabatake M; Hashida T; Chung H; Inokuma T; Muroi N
Biol Pharm Bull; 2022; 45(3):333-338. PubMed ID: 35228399
[TBL] [Abstract][Full Text] [Related]
30. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
[TBL] [Abstract][Full Text] [Related]
31. Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma.
Nagai H; Mukozu T; Kobayashi K; Nogami A; Nagumo H; Mohri K; Watanabe G; Amanuma M; Yoshimine N; Ogino Y; Matsui D; Daido Y; Matsukiyo Y; Matsui T; Wakui N; Momiyama K; Higai K; Matsuda T
Oncology; 2023; 101(1):32-40. PubMed ID: 36191570
[TBL] [Abstract][Full Text] [Related]
32. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.
Miyajima S; Tsuji K; Kito Y; Yoshida N; Matsunaga K; Tsuji S; Katayanagi K; Yonezawa M; Kubo A; Ushijima K; Minato H; Doyama H
Clin J Gastroenterol; 2021 Feb; 14(1):187-192. PubMed ID: 33025343
[TBL] [Abstract][Full Text] [Related]
33. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
[TBL] [Abstract][Full Text] [Related]
34. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma.
Kim BH; Yu SJ; Kang W; Cho SB; Park SY; Kim SU; Kim DY
J Gastroenterol Hepatol; 2022 Mar; 37(3):428-439. PubMed ID: 34725855
[TBL] [Abstract][Full Text] [Related]
35. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
36. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Rapposelli IG; Tada T; Shimose S; Burgio V; Kumada T; Iwamoto H; Hiraoka A; Niizeki T; Atsukawa M; Koga H; Hirooka M; Torimura T; Iavarone M; Tortora R; Campani C; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Giuseppe Foschi F; Silletta M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Tanaka T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Rimini M; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
Liver Int; 2021 Dec; 41(12):2997-3008. PubMed ID: 34250737
[TBL] [Abstract][Full Text] [Related]
37. [A Case of Advanced Hepatocellular Carcinoma That Caused Rapid Re-Growth Due to Lenvatinib Withdrawal].
Oyama K; Maeda S; Nakahira S; Kitagawa A; Ushimaru Y; Ohara N; Miyake Y; Makari Y; Nakata K; Fujita J
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1586-1588. PubMed ID: 35046264
[TBL] [Abstract][Full Text] [Related]
38. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
39. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
[TBL] [Abstract][Full Text] [Related]
40. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
